MDLN MDLN
Company Profile ↓Company Overview
MDLN (MDLN) is a publicly traded company listed on with a market capitalization of $29.77B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 10.6% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $28.43B (+11.5% YoY); net profit $1.16B.
- Trailing 12 Months Year-on-year growth — revenue +11.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 10.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 10.63% |
| 1 Year: | 11.47% |
Stock Price Performance
| 1 Year: | -10.57% |
| 6 Months: | -18.01% |
| 3 Months: | -19.10% |
| 1 Month: | -14.75% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)41.94 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 10.6% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 26.7% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 6.64B | 7.35B |
| Gross Profit | 1.82B | 1.84B |
| Operating Income | 571.00M | 422.00M |
| Net Income | 319.00M | - |
| Diluted EPS | - | 0.16 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 23.23B | 25.51B | 28.43B |
| Gross Profit | 5.88B | 6.98B | 7.52B |
| Operating Income | 1.25B | 2.15B | 2.21B |
| Net Income | - | - | 1.16B |
| Diluted EPS | - | - | -0.01 |
| R&D Expense | 60.00M | 67.00M | 80.00M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | - | - | 38.48B |
| Current Assets | - | - | 10.68B |
| Cash & Equivalents | - | - | 1.94B |
| Inventory | - | - | 4.77B |
| Receivables | - | - | 3.53B |
| Total Liabilities | - | - | 19.20B |
| Current Liabilities | - | - | 2.49B |
| Long Term Debt | - | - | 12.48B |
| Total Debt | - | - | 12.63B |
| Total Equity | 55.00M | 16.52B | 10.74B |
| Shares Outstanding | 799.80M | 812.00M | 812.00M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | 1.69B | 1.77B | 1.74B |
| Investing Cash Flow | -312.00M | -1.49B | -474.00M |
| Financing Cash Flow | -191.00M | -1.61B | 399.00M |
| Capital Expenditure | -275.00M | -354.00M | -447.00M |
| Free Cash Flow | 1.41B | 1.42B | 1.30B |
| Share Buybacks | 0 | 20.00M | 33.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | 25.3% | 27.3% | 26.4% |
| Operating Margin % | 5.4% | 8.4% | 7.8% |
| Net Margin % | - | - | 4.1% |
| ROE % | - | - | 10.8% |
| ROCE % | - | - | 6.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MDLN
Top Medline (MDLN) Competitors 2026 - MarketBeat
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxPT1ppZk5OdzU0dDRKUTVWTVNkTk9paWpnbGZrV0p3c3prdEV5VmRRYWg5bkZ5Z3doSG9FRDBtZnNaNWJqN3g0bWVrdnJsWWNXY2FwT3FNUnRocEx5LXlXNDlqdTZzVzhlTlk5YkRka1NmcHZOTzA1RHVoMWQwNVpZdQ?oc=5" target="_…
$MDLN stock is down 15% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPYjJQUUlsR1NDem5Wa1dmREpENEhxN2lZLWV6ajkxSkduMUFtUlQ2TzNYYnZUbDBnRXVCS3FldUE1LUxZMXdCd0dxdDFjMnV2YWxIWTlYYU5idG5NMTBQQ25CZUxuM1FFMEdCelY4cFVOcy0yR3g0a1g4YTFOSlJ4NGdzWDFlWk16bTl6Yl…
Here's What Key Metrics Tell Us About Medline (MDLN) Q2 Earnings - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxPNG9iQjVTMm5SQUsxLUpjMmlUZXhIem01bjRQbWNGY1VjWVFUeG5iSTUweEVaZlBxaTNRZDNOYVJIbFdBRENwQnJtR3d0RDVyOHREcWwwNzg4b2pKY2dEakNMbVFVV0VfZ3o1c0NkUXhqV1dlX1ZZWDlkYU5ZMmh4Y0xXN09LdEJiSEt4YX…
Medline Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:MDLN) 2026-08-05 - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNZEFyTUtlaUxkRmp4d1FmY3dtM2JZZV9qOGhOZlRTTXdXMkFsTktsN1ptQUEzQlRKNWFIYzZZZmVXc255OFN3ekxzWExVSmRVSE1EX0VENW1SelZHeElacEk2bTlTbjVPUzBTRHRmYk5yelFCRjBoWnpkUzJqUFRyZy1OSGVVUjQ4Mzg3LT…
Earnings Flash (MDLN) Medline Inc. Posts Q2 Adjusted EPS $0.50 per Share, vs. FactSet Est of $0.32 - marketscreener.com
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxQdDhoOEYtRndWX0pYcmtZNUJVaDBTaFg5NEpGSFFRZmNqNnVjQWp6ZW5OMWluWE9OMDVVNl94ZlNqWWlxUGN4S0F1UGNWcWg0QVJQR0YwMlpCT2VGNktFV0ZjZUJuZ2xsai1hSDRvVC1ZNHBNNVU4R2l0ZW52aW9qekt5NWJyeGdBMkZ5S0…
MDLN News Today | Why did Medline stock drop today? - MarketBeat
<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE9EZWo3YVBkVHhTT2VaY3VoT2VnSXBMQ29xTTg2N1hkS25CRUdORG9iMnY2VVdMY3FQenhORlJtVUVQSC10dVBHNzRucjgxa1hQSTNBSDRmWHFndGtCUExqbg?oc=5" target="_blank">MDLN News Today | Why did Medline sto…
MDLN — Frequently Asked Questions
What is the current share price of MDLN?
As of 2026-08-05 17:25 PDT, MDLN trades at $36.66 on NASDAQ/NYSE. Its 52-week range is $33.19 to $49.99.
What is the market capitalisation of MDLN?
MDLN has a market capitalisation of $29.77B on NASDAQ/NYSE.
What is the return on equity (ROE) of MDLN?
MDLN has a return on equity (ROE) of 10.79%. Its return on capital employed (ROCE) is 6.15%.
Is MDLN a good stock to buy?
This page provides a data-driven analysis of MDLN, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.